|
|||||
|
|
Phase I study of BAY 94‐9027, a PEGylated B‐domain‐deleted recombinant factor VIII with an extended half‐life,in subjects with hemophilia A |
|
| Authors: | T. E. Coyle M. T. Reding J. C. Lin L. A. Michaels A. Shah J. Powell |
| Abstract: | |
| Keywords: | clinical trial, Phase 1 factor VIII hemophilia A pharmacokinetics recombinant proteins |